The biotech industry has made a splash in 2017, outperforming practically all the broad markets. With this incredible display, it’s no wonder that investor interest in this particular industry has grown, and one analyst sees this continuing even further.
Jefferies is fundamentally positive on the biotech sector, considering that the group has been primarily a laggard and underweight by institutional investors. Not to mention this group is not expensive compared with other subgroups and the market.
